Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Notes Payables: 2013-2023

Historic Notes Payables for Fortress Biotech (FBIO) over the last 8 years, with Mar 2023 value amounting to $3.0 million.

  • Fortress Biotech's Notes Payables was N/A to $3.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.9 million for FY2022, which is 263.05% up from last year.
  • Fortress Biotech's Notes Payables amounted to $3.0 million in Q1 2023, which was up 1.76% from $2.9 million recorded in Q4 2022.
  • Over the past 5 years, Fortress Biotech's Notes Payables peaked at $86.0 million during Q2 2020, and registered a low of $812,000 during Q4 2021.
  • Over the past 3 years, Fortress Biotech's median Notes Payables value was $3.0 million (recorded in 2023), while the average stood at $4.5 million.
  • As far as peak fluctuations go, Fortress Biotech's Notes Payables crashed by 93.60% in 2021, and later skyrocketed by 263.05% in 2022.
  • Over the past 5 years, Fortress Biotech's Notes Payables (Quarterly) stood at $7.2 million in 2019, then slumped by 38.83% to $51.4 million in 2020, then slumped by 79.67% to $812,000 in 2021, then spiked by 263.05% to $2.9 million in 2022, then reached $3.0 million in 2023.
  • Its Notes Payables stands at $3.0 million for Q1 2023, versus $2.9 million for Q4 2022 and $812,000 for Q4 2021.